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ABSTRACT 1 
Excessive glucocorticoid exposure has been shown to be deleterious for pancreatic beta cell 2 
function and insulin release. However, glucocorticoids at physiological levels are essential 3 
for many homeostatic processes, including glycemic control. Here, we show that 4 
corticosterone and cortisol and their less active precursors, 11-dehydrocorticosterone (11-5 
DHC) and cortisone, suppress voltage-dependent Ca
2+ 
channel function and Ca
2+
 fluxes in 6 
rodent as well as human beta cells. However, insulin secretion, maximal ATP/ADP responses 7 
to glucose and beta cell identity were all unaffected. Further examination revealed the 8 
upregulation of parallel amplifying cAMP signals, and an increase in the number of 9 
membrane-docked insulin secretory granules. Effects of 11-DHC could be prevented by 10 
lipotoxicity and were associated with paracrine regulation of glucocorticoid activity, since 11 
global deletion of 11β-hydroxysteroid dehydrogenase type 1 normalized Ca2+ and cAMP 12 
responses. Thus, we have identified an enzymatically-amplified feedback loop whereby 13 
steroid boosts cAMP to maintain insulin secretion in the face of perturbed ionic signals. 14 
Failure of this protective mechanism may contribute to diabetes in states of glucocorticoid 15 
excess such as Cushing’s syndrome, which are associated with frank dyslipidemia.  16 
  17 
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INTRODUCTION 1 
Circulating glucocorticoids exert potent metabolic effects including lipolysis, hepatic 2 
gluconeogenesis, amino acid mobilization and reduced skeletal muscle glucose uptake (1). 3 
This is facilitated by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1), 4 
which (re)activates glucocorticoid in a tissue-specific manner to determine bioavailability (2). 5 
As such, states of excess glucocorticoids (e.g. as seen during Cushing’s syndrome) are pro-6 
diabetic, since they cause profound glucose intolerance and insulin resistance.  7 
While systemic administration of glucocorticoids induces a compensatory increase in 8 
beta cell mass, and eventually insulin secretory failure due to insulin resistance (3), effects 9 
directly on beta cell function are less well understood. Suggesting an important link between 10 
glucocorticoids and insulin release, beta cell-specific glucocorticoid receptor (GR) 11 
overexpression reduces glucose tolerance (4). However, in vitro studies using isolated islets 12 
have shown inhibitory or no effect of glucocorticoids on glucose-stimulated insulin secretion 13 
depending on the steroid potency, concentration and treatment duration (5-9). By contrast, 14 
HSD11B1 increases ligand availability at the GR by converting less active to more active 15 
glucocorticoid (11-dehydrocorticosterone (11-DHC) -> corticosterone in rodents; cortisone -16 
> cortisol in man), impairing beta cell function in islets both in vitro and in vivo (6; 10; 11). 17 
Whereas 11-DHC has consistently been shown to impair beta cell function in islets from 18 
obese animals, conflicting reports exist regarding its effects on normal islets (7; 10). 19 
More generally, the signaling components targeted by glucocorticoids are not well 20 
defined. While exogenous application of glucocorticoid subtly decreases insulin release, and 21 
nicotinamide adenine dinucleotide phosphate, 3',5'-cyclic adenosine monophosphate (cAMP) 22 
and inositol phosphate production (5), these studies were performed using high dose 23 
dexamethasone (25x relative potency). Conversely, administration of the same glucocorticoid 24 
in drinking water augments insulin release by increasing the number of docked exocytotic 25 
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vesicles, as well as beta cell mitochondrial potential/metabolism (12). However, indirect 1 
effects of insulin resistance cannot be excluded, as studies in high fat diet-fed mice have 2 
shown that compensatory beta cell responses, including proliferation, occur within a few days 3 
(13). Lastly, glucocorticoid administration or GR deletion in the early neonatal period alters 4 
beta cell development, leading to reductions in the expression of key maturity markers 5 
including Pdx1, Nkx6.1 and Pax6 (14; 15). Whether this is also seen in adult islets, as may 6 
occur during diabetes (16), is unknown. 7 
In the present study, we therefore sought to investigate the mechanisms by which the 8 
endogenous glucocorticoids corticosterone and cortisol affect beta cell function. Using in situ 9 
imaging approaches together with specific biosensors, we reveal that glucocorticoids perturb 10 
cytosolic Ca
2+
 concentration through effects on voltage-dependent Ca
2+ 
channel function, 11 
without altering beta cell maturity, glucose-induced changes in ATP/ADP ratio or incretin 12 
responsiveness. This however does not lead to reduced insulin secretion, since 13 
glucocorticoids upregulate parallel cAMP signaling pathways. The less active glucocorticoids 14 
11-DHC and cortisone showed identical effects, which could be reversed in mouse following 15 
global deletion of Hsd11b1. Thus, a steroid-regulated feedback loop, encompassing an 16 
enzymatic amplification step, maintains normal insulin secretory output in the face of 17 
impaired beta cell ionic fluxes.  18 
  19 
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MATERIALS AND METHODS 1 
Animals 2 
CD1 mice (8-12 weeks, males) were used as wild-type tissue donors.  Hsd11b1
-/-
 mice were 3 
generated as described (17). Studies were regulated by the Animals (Scientific Procedures) 4 
Act 1986 of the United Kingdom, and approval granted by the University of Birmingham’s 5 
Animal Welfare and Ethical Review Body. 6 
Islet isolation 7 
Islets were isolated using collagenase digestion and cultured in RPMI supplemented with 8 
10% fetal calf serum, 100 U/mL penicillin and 100 µg/mL streptomycin. Vehicle (ethanol 9 
0.2%), 11-DHC (20 or 200 nM) or corticosterone (20 nM) (i.e. within the normal circulating 10 
free glucocorticoid range) were applied for 48 hrs. BSA-conjugated palmitate was applied at 11 
0.5 mM.  12 
Human islet culture 13 
Islets were obtained from isolation centers at Alberta (IsletCore) (18), Pisa and Milan, with 14 
local and national ethical permissions. Islets were cultured  in RPMI containing 10% fetal 15 
calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml fungizone, 16 
supplemented with 5.5 mM D-glucose, and treated with either vehicle (ethanol 0.2%), 17 
cortisone (200 nM) or cortisol (20 nM) applied for 48 hrs. See Supplemental Table 1 for 18 
donor characteristics. Studies were approved by the National Research Ethics Committee 19 
(NRES), REC reference 16/NE/0107. 20 
Calcium, ATP/ADP and cAMP imaging 21 
Islets were loaded with 10 µM Fluo8 AM for 45 mins at 37 °C before washing and 22 
incubation in buffer for a further 30 min to allow cleavage by intracellular esterase. Imaging 23 
was conducted using either: 1) a Crest X-Light spinning disk and 10 x/0.4 NA objective; or 24 
2) a Zeiss LSM780 and 10 x/0.45 NA objective. For the Crest system, excitation was 25 
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delivered at λ = 458–482 nm (400 ms exposure; 0.33 Hz) and emitted signals detected at λ = 1 
500–550 nm using an EMCCD. For the Zeiss system, excitation was delivered at λ = 488 nm, 2 
and emitted signals detected at λ = 499–578 nm using a PMT. Fura2 was loaded as for Fluo8 3 
and imaging performed using LEDs (excitation λ = 340/385 nm; emission λ = 470-550 nm). 4 
ATP/ADP ratios and cAMP responses were measured using adenovirus harboring 5 
either Perceval (excitation/emission as for Fluo8) or the FRET probe Epac2-camps 6 
(excitation λ = 430-450 nm; emission λ = 460-500 nm and 520-550 nm) (19; 20). For 7 
Perceval, glucose was increased from 3-11 mM, which leads to plateau responses (21). An 8 
effect of glucocorticoid on Epac2-camps expression was unlikely, since single and dual 9 
channel fluorescence under maximal stimulation was similar for all treatments (Supplemental 10 
Table 2). HEPES-bicarbonate buffer was used, containing (in mM): 120 NaCl, 4.8 KCl, 24 11 
NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2, 1.2 MgCl2, 8 D-glucose. Ca
2+
, cAMP and 12 
ATP/ADP traces were normalized as F/Fmin, where F = fluorescence at any given time point 13 
and Fmin = minimum fluorescence during the recording (i.e. under basal conditions). 14 
Electrophysiology 15 
VDCC currents were recorded from dispersed mouse beta cells, as previously described (22). 16 
Patch electrodes were pulled to a resistance of 3-4 MΩ then filled with an intracellular 17 
solution containing (in mM): 125 CsCl, 10 tetraethylammonium Cl (TEA), 1 MgCl2, 5 18 
EGTA, 10 HEPES, 3 MgATP, pH 7.22 with CsOH. Cells were patched in HEPES-buffered 19 
solution + 17 mM glucose. upon obtaining the whole-cell configuration with a seal resistance 20 
> 1 GΩ, the bath solution was exchanged for a modified HEPES-buffered solution containing 21 
(in mM): 62 NaCl, 20 TEA, 30 CaCl2, 1 MgCl2, 5 CsCl, 10 HEPES, 17 glucose, 0.1 22 
tolbutamide, pH 7.35 with NaOH. Beta cells were perfused for three minutes with this 23 
solution prior to initiating the VDCC recording protocol. Voltage steps of 10 mV were 24 
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applied from a holding potential of -80 mV; linear leak currents were subtracted online using 1 
a P/4 protocol. Data were analyzed using Clampfit software (Molecular Devices). 2 
Immunohistochemistry and super-resolution imaging 3 
Islets were fixed overnight at 4ºC in 4% parafolmadehyde before immunostaining using 4 
rabbit monoclonal anti-insulin (Cell Signaling Technology; 1:400) and goat anti-rabbit 5 
Alexa568 (1:1000). Super-resolution imaging was performed using a VisiTech iSIM and a 6 
100x/1.49 NA objective. Excitation was delivered using a λ = 561 nm and emitted signals 7 
captured at λ = 633-647 nm using a sCMOS. Image stacks were cropped to include only the 8 
near-membrane regions and exclude out-of-focus signal, converted to 8-bit grayscale, before 9 
obtaining the maximum intensity projection. Auto-thresholding was performed in Fiji (NIH) 10 
to produce a binary snapshot from which the area occupied by insulin granules could be 11 
quantified as a unitary ratio (V/v) versus the total membrane area using the analyze particle 12 
plugin, as previously described (20).  13 
Real-time PCR 14 
Relative mRNA abundance was determined using SYBR Green chemistry and fold-change in 15 
mRNA expression calculated compared to Actb using the 2
–ΔΔCt
 method (see Supplemental 16 
Table 3 for primer sequences). Hsd11b1 mRNA abundance was determined using TaqMan 17 
assays for mouse (Cat. # 4331182) and human (Cat. # 4331182) tissue, Hsd11b1 expression 18 
calculated using 2
–ΔCt
 x 1000, and transformed values presented as arbitrary units. 19 
Measurements of insulin secretion and ATP in isolated islets 20 
Batches of eight islets were placed in low-bind Eppendorf tubes, incubated for 30 mins at 37 21 
°C in HEPES-bicarbonate buffer containing 3 mM glucose, before addition of either 3 mM 22 
glucose, 17 mM glucose or 17 mM glucose + 10 mM KCl for a further 30 mins and 23 
collection of supernatant. Total insulin was extracted into acid-ethanol. Insulin concentration 24 
was determined using a Homogeneous Time Resolved Fluorescence (HTRF)-based assay 25 
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(Cisbio) according to the manufacturer’s instructions. Total ATP at 3 and 17 mM glucose 1 
was measured in batches of 25 islets using a luciferase-based assay (Invitrogen), and values 2 
normalized to total protein.   3 
Statistical analyses 4 
Pairwise comparisons were performed using paired or unpaired Student’s t-test. Interactions 5 
between multiple treatments were determined using one-way ANOVA (adjusted for repeated 6 
measures as necessary), followed by pairwise comparisons with Bonferonni’s or Tukey’s post 7 
hoc test. Analyses were conducted using Graphpad Prism and IgorPro.  8 
  9 
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RESULTS 1 
Glucocorticoids alter ionic but not metabolic fluxes  2 
Fluo8-loaded beta cells residing within intact islets of Langerhans were subjected to 3 
multicellular Ca
2+
-imaging approaches (23). Individual beta cells responded to elevated 4 
glucose (3 mM -> 17 mM) with large increases in cytosolic Ca
2+
 levels (Fig. 1A and B). 5 
Whereas 11-DHC 20 nM was without effect, higher (200 nM) concentrations suppressed the 6 
amplitude and area-under-the-curve (AUC) of Ca
2+
 rises in response to glucose and glucose + 7 
KCl by ~30% (Fig. 1A-E) (Supplemental Fig. 1A and B) (Supplemental Fig. 2A-C), and this 8 
reached ~50% in the presence of corticosterone 20 nM. Results could be confirmed using the 9 
ratiometric Ca
2+
 indicator Fura2, excluding a major contribution of  basal Ca
2+
 levels to the 10 
magnitude changes detected here (Supplemental Fig. 2A-C). No effect of glucocorticoid on 11 
the time to onset of Ca
2+
 rises was detected (lag period ± SD = 22.5 ± 7.7 versus 26.3 ± 9.7 12 
versus 24.0 ± 6.2 s for control, 11-DHC and corticosterone, respectively; non-significant, 13 
one-way ANOVA). The peak Ca
2+
 response to KCl depolarization in 3 mM glucose was 14 
unaffected by 11-DHC and significantly increased by corticosterone (Supplemental Fig. 2D 15 
and E), although both glucocorticoids reduced Ca
2+
 amplitude when KCl concentration was 16 
increased from 10 to 30 mM (Supplemental Fig. 2F and G) (24). While 11-DHC and 17 
corticosterone both led to more sustained Ca
2+
 influx in response to 10 mM KCl 18 
(Supplemental Fig. 2E), this was not the case with 30 mM KCl (Supplemental Fig. 2G). An 19 
effect of treatment on basal Ca
2+
 levels at 3 mM glucose was unlikely, since the Fura2 20 
340/385 ratio was not significantly affected by 11-DHC or corticosterone (Supplemental Fig. 21 
2H). 22 
Supporting an action on later steps in ionic flux generation, 11-DHC and 23 
corticosterone reduced Ca
2+
 oscillation frequency at moderately (11 mM) elevated glucose 24 
concentration (Fig. 1F and G). Glucocorticoids (cortisone and cortisol) also suppressed Ca
2+
 25 
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responses to glucose and glucose + KCl in human islets (Fig. 1H-J), without significantly 1 
altering basal Ca
2+ 
concentration (Supplemental Table 4). The reported glucocorticoid actions 2 
were specific to glucose, as both 11-DHC and corticosterone were unable to influence Ca
2+
 3 
responses to exendin-4 in mouse islets in terms of oscillation frequency and AUC (Fig. 1K-4 
M), these parameters being the primary drivers of incretin-stimulated Ca
2+
 fluxes in this 5 
species (23).  6 
Beta cells remain differentiated in the presence of glucocorticoid 7 
Immature or de-differentiated beta cells fail to respond properly to glucose, a defect that can 8 
partly be explained by lowered transcription factor expression, and impairments in 9 
metabolism and Ca
2+
 flux generation (25). This was unlikely to be the case here, however, as 10 
11-DHC and corticosterone did not significantly affect mRNA abundance of the key beta cell 11 
maturity markers Pdx1 (Fig. 2A-C) and Nkx6.1 (Fig. 2D-F). Moreover, maximal ATP/ADP 12 
increases in response to glucose, measured using the biosensor Perceval (26), were not 13 
significantly different (Fig. 2G and H). 11-DHC and corticosterone did not affect the time to 14 
onset (Supplemental Fig. 3A) or the amplitude (Supplemental Fig. 3B) of the initial, transient 15 
decrease in ATP/ADP. No significant effects of glucocorticoid on basal or glucose-stimulated 16 
ATP levels were detected using luciferase-based assays (Supplemental Fig. 4). Patch-clamp 17 
electrophysiology revealed abnormal VDCC function in the presence of glucocorticoids, with 18 
voltage-current (I-V) curves showing a marked reduction in Ca
2+
 conductance (Fig. 2I and J). 19 
Suggestive of changes in VDCC function rather than expression, transcript levels of the 20 
major alpha and beta subunits Cacna1c (Fig. 2K and L), Cacnb2 (Fig. 2M and N) and 21 
Cacna1d (Fig. 2O and P) were not significantly altered.  22 
Glucocorticoids do not affect insulin secretory responses 23 
In response to glucose, increases in ATP/ADP ratios lead to closure of KATP-channels, 24 
opening of VDCCs and Ca
2+
-dependent insulin secretion (27). Thus, perturbed cytosolic Ca
2+
 25 
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fluxes/levels generally translate to reductions in insulin secretory output (27). However, 1 
glucose and glucose + KCl-stimulated insulin release were not significantly different 2 
following 48 hr exposure of islets to 11-DHC or corticosterone (Fig. 3A). This was not due to 3 
an increase in insulin expression, since Ins1 mRNA levels were similar in the presence of 4 
both glucocorticoids (Fig. 3B-D). Likewise, total insulin content was not significantly 5 
different between treatments under all stimulation conditions examined (Fig. 3E). Insulin 6 
secretion was also unaffected by cortisone and cortisol treatment in primary human islets 7 
(Fig. 3F and G) (Supplemental Table 1).  8 
cAMP signals are upregulated by glucocorticoid 9 
Granule release competency can be increased by signals including cAMP, which acts directly 10 
upon protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (Epac2) 11 
(28). Using the FRET probe Epac2-camps to dynamically report cytosolic cAMP (20), 12 
glucose induced a robust increase in levels of the nucleotide (Fig. 4A). 11-DHC and 13 
corticosterone both upregulated cAMP responses to glucose by approximately 1.5-fold (Fig. 14 
4A-C). This appeared necessary for maintenance of secretory output, since chemical 15 
inhibition of PKA significantly reduced glucose-stimulated insulin release in 11-DHC-treated 16 
islets (Fig. 4D). Indeed, more granules were present at the membrane in glucocorticoid-17 
treated islets, revealed using super-resolution structured illumination microscopy (SIM) (Fig. 18 
4E and F). Similar results were seen in human islets, with cortisone and cortisol both 19 
augmenting cAMP responses to glucose (Fig. 4G and H). As for Ca
2+
, the actions of 20 
glucocorticoid were glucose-specific, as neither 11-DHC nor corticosterone altered cAMP 21 
responses to exendin-4 (Fig. 4I and J). Supporting a central role for adenylate cyclase (Adcy) 22 
in this effect, expression of Adcy1 was increased by both glucocorticoids (Fig. 4K and L), and 23 
induction of lipotoxicity with palmitate- shown previously to lower Adcy9 mRNA (29)- 24 
prevented glucocorticoid from augmenting cAMP responses to glucose (Fig. 4M and N).  25 
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Hsd11b1 is expressed in islets of Langerhans 1 
HSD11B1 is responsible for catalyzing the conversion of 11-DHC to corticosterone and is an 2 
important mechanism that determines local glucocorticoid activity (30). Expression of 3 
Hsd11b1 in islets has previously been shown to be sufficient for 11-DHC  corticosterone 4 
conversion (7). We therefore repeated studies in islets obtained from mice globally lacking 5 
one (Hsd11b1
+/-
) or both (Hsd11b1
-/-
) alleles of Hsd11b1. While Hsd11b1 mRNA levels were 6 
low in mouse islets compared to liver and muscle, it was still detectable (ΔCt = 7.33. ± 1.80) 7 
(Supplemental Fig. 5A). Moreover, Hsd11b1 mRNA abundance was 55-75% lower in islets 8 
from animals expressing a single copy of Hsd11b1 and undetectable in those deleted for both 9 
alleles (Supplemental Fig. 5B), as assessed using specific TaqMan assays. Quantification of 10 
HSD11B1 mRNA revealed similar levels in human and mouse islets, with expression an 11 
order of magnitude lower than in human subcutaneous and omental adipose tissue 12 
(Supplemental Fig. 5C), a major site of enzyme activity and steroid reactivation (31).  13 
Hsd11b1
 
deletion reverses the effects of glucocorticoids on beta cell Ca
2+
 and cAMP 14 
signaling  15 
As expected, both 11-DHC and corticosterone impaired cytosolic Ca
2+
 fluxes in beta cells 16 
residing within islets from Hsd11b1
+/- 
animals (Fig. 5A-D) (Supplemental Fig. 6A and B). 17 
However, deletion of Hsd11b1
-/-
 throughout the islet reversed these effects, with 11-DHC and 18 
corticosterone no longer able to suppress Ca
2+
 rises in response to glucose- or glucose + KCl 19 
(Fig. 5E-H) (Supplemental Fig. 6C and D). This suggests that local regulation of 20 
glucocorticoid activity in the islet may mediate the effects of 11-DHC and corticosterone on 21 
beta cell Ca
2+
 fluxes. 11-DHC was able to significantly elevate cAMP responses to glucose in 22 
Hsd11b1
+/- 
(Fig. 6A-D) (Supplemental Fig. 7A), but not Hsd11b1
-/-
 islets (Fig. 6E-H) 23 
(Supplemental Fig. 7B). However, corticosterone still improved cAMP responses to glucose, 24 
even following deletion of Hsd11b1 (Fig. 6A-H) (Supplemental Fig. 7A and B). Glucose-25 
13 
 
stimulated insulin secretion was significantly higher in corticosterone- versus control- or 11-1 
DHC-treated Hsd11b1
-/- 
islets (Fig. 6I), consistent with the Ca
2+
 and cAMP results. Similarly, 2 
QRT-PCR analyses revealed upregulation of Adcy1 expression by corticosterone, but not 11-3 
DHC, in Hsd11b1
-/- 
islets (Fig. 6J and K). Ca
2+ 
responses to glucose, glucose + KCl and KCl 4 
were not significantly decreased by 11-DHC (Fig. 7A-D) (Fig. 7E and F) (Supplemental Fig. 5 
8A and B) in islets pre-treated with RU486.  Similarly, corticosterone was unable to impair 6 
Ca
2+
 responses to glucose and KCl in RU486-treated islets (Fig. 7E) (Supplemental Fig. 8C 7 
and D), although Ca
2+
 responses to glucose + KCl were unaffected (Fig. 7F). Thus, the 8 
inhibitory actions of the glucocorticoids are partly mediated by the GR. 9 
  10 
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DISCUSSION 1 
We show here that corticosterone and cortisol and their less active precursors, 11-DHC and 2 
cortisone, impair glucose-, glucose + KCl- and KCl-stimulated ionic fluxes in rodent and 3 
human beta cells. However, insulin secretory output is likely preserved because both 4 
glucocorticoids upregulate signals from the cAMP pathway to increase the number of insulin 5 
granules located in the vicinity of the membrane. Invoking a critical role for glucocorticoid 6 
interconversion, the effects of 11-DHC could be prevented following islet-wide deletion of 7 
the rate-limiting enzyme HSD11B1. Thus, an enzyme-assisted steroid-regulated feedback 8 
loop maintains insulin secretion in the face of altered beta cell ionic signaling (Fig. 8).  9 
 Both corticosterone and 11-DHC have previously been shown to exert inhibitory 10 
effects on insulin release (6; 7; 10; 11). However, these studies either used islets from ob/ob 11 
mice that display highly upregulated Hsd11b1 expression (6; 10), or incubated wild-type 12 
islets with glucocorticoid for only two hours (7; 11), which is unlikely to fully compensate 13 
the loss of adrenal input expected to occur following islet isolation. Likewise, studies in 14 
which glucocorticoids are administered in the drinking water are confounded by insulin 15 
resistance and compensatory islet expansion (i.e. any in vitro assessment may reflect a pre-16 
diabetic state) (12). Thus, the effects observed in the present study more likely reflect the 17 
cellular/molecular actions of circulating glucocorticoids under normal conditions.  18 
Cytosolic Ca
2+
 responses to glucose were impaired in the presence of either 11-DHC 19 
or corticosterone. This was unlikely due to defects in metabolism and KATP-channel function, 20 
since glucose-induced ATP/ADP maximal rises were unaffected. However, KCl- and KCl + 21 
glucose-induced Ca
2+ 
influx, as well as VDCC conductance, were markedly suppressed, 22 
although QRT-PCR analyses of expression levels of the key L-type VDCC subunits showed 23 
no differences. Thus, glucocorticoids likely induce changes in VDCC function that restrict 24 
Ca
2+
 entry. Ca
2+
 oscillation frequency was also affected, suggesting that glucocorticoids may 25 
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also conceivably target more distal steps in Ca
2+
 flux generation, such as intracellular stores 1 
(e.g. by depleting them through cAMP sensitization of IP3 receptors (32)), upregulate ion 2 
channels involved in voltage-inactivation (i.e. large-conductance Ca
2+-
activated K
+
 channels 3 
(33)), or alter glucose-regulated inputs other than cAMP (34). These effects are presumably 4 
specific to glucose-stimulated Ca
2+ 
rises, as responses to the incretin mimetic exendin 4 5 
remained unchanged by glucocorticoid exposure, possibly due to PKA-mediated rescue of 6 
VDCC function or organellar Ca
2+
 release (35).  7 
Recent RNASeq analyses of purified mouse beta cells have shown that Hsd11b1 8 
mRNA levels are unusually low in these and other islet neuroendocrine cells (i.e. it is an islet 9 
“disallowed” gene) (36). Likewise, HSD11B1 mRNA levels were low in human beta and 10 
alpha cells (37). These findings contrast with reports that protein expression co-localizes with 11 
glucagon or insulin in rodent islets depending on the antibody used (7; 38). The reasons for 12 
these discrepancies are unclear, but in the present study specific TaqMan assays showed 13 
consistently detectable mRNA levels in both rodent and human islets. Moreover, 11-DHC 14 
effects could be prevented in global Hsd11b1
-/-
 islets in which mRNA was largely absent, and 15 
HSD11B1 expression in human islets was an order of magnitude lower than in adipose tissue, 16 
a major site for steroid reactivation after the liver (31). Thus, 11-DHC likely affects beta cell 17 
function in a paracrine manner, possibly through the actions of HSD11B1 in non-endocrine 18 
islet cell types (e.g. endothelial cells where expression levels are relatively high (37)). This 19 
may form the basis of an adaptive mechanism to prevent the build-up of high local 20 
corticosterone/cortisol concentrations. Together, these data highlight the importance of the 21 
islet context for the regulation of insulin secretion, and underline the requirement to consider 22 
cell-cell cross-talk when assessing the functional consequences of beta cell gene 23 
disallowance.   24 
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Global deletion of Hsd11b1 prevented the effects of 11-DHC on ionic and cAMP 1 
fluxes, as expected, suggesting that local regulation of glucocorticoid activity is important for 2 
beta cell function. However, corticosterone was unable to impair Ca
2+
 responses in Hsd11b1
-/-
 3 
islets, whereas potentiation of cAMP remained intact. Together, these observations raise the 4 
possibility that corticosterone may undergo substantial oxidation to 11-DHC via HSD11B2, 5 
also shown to be expressed in the islet (37), with local concentrations dropping below the 6 
threshold for suppression of Ca
2+
 but not cAMP following Hsd11b1 knockout. While 7 
previous studies have shown that a single Hsd11b1 allele is sufficient for full enzymatic 8 
activity (39), further studies are required to determine whether this is also the case in islets.  9 
Consistent with upregulated cAMP signaling, an increase in the number of sub-10 
membrane insulin granules was observed in islets treated with glucocorticoid for 48 hrs. 11 
Indeed, cAMP has been shown to recruit non-docked insulin granules to the membrane, as 12 
well as increase the size of the readily-releasable granule pool via Epac2 and PKA (40; 41), 13 
and this would be expected to account for the intact secretory responses to glucose and KCl. 14 
The exact mechanisms by which 11-DHC and corticosterone boost cAMP signaling are 15 
unknown, but likely involve specific adenylate cyclases, since Adcy1 gene expression was 16 
increased in 11-DHC- and corticosterone-treated islets compared to controls. Moreover, 17 
palmitate, which downregulates Adcy9 and impairs cAMP responses to glucose (29), was 18 
found to prevent 11-DHC from increasing cAMP levels. While Adcy9 mRNA expression was 19 
not significantly affected by glucocorticoid, other mechanisms can account for cAMP 20 
generation, including organization of the enzyme into microdomains (42). Pertinently, Adcy1 21 
and Adcy9 knockdown have been shown to reduce glucose-stimulated cAMP rises and insulin 22 
secretion in beta cells (29; 43). Further studies are thus warranted in glucocorticoid-treated 23 
Adcy1- and Adcy9-null islets. Upregulated cAMP signaling may represent a protective 24 
mechanism that is disrupted by free fatty acids to induce beta cell failure/decompensation in 25 
17 
 
the face of excess glucocorticoid. Of note, endogenous elevation of glucocorticoids leads to 1 
dyslipidemia due to lipolysis, de novo fatty acid production/turnover and hepatic fat 2 
accumulation (44).  3 
It has previously been shown in mouse islets that cAMP responses to glucose are 4 
oscillatory (29), albeit more noisy than those in MIN6 and INS-1E cells (45). However, the 5 
latter studies used TIRF microscopy to study sub-plasma membrane-localized cAMP 6 
responses, whose changes may be larger and more dynamic than those recorded throughout 7 
the cytosol, probably due to proximity to VDCCs (46). Indeed, similar studies using 8 
epifluorescence techniques show non-oscillatory cAMP increases in response to high glucose 9 
concentrations (47). Thus, at the axial resolutions employed here, cAMP oscillations in intact 10 
islets may not be detectable, and further studies are required to investigate the impact of 11 
glucocorticoids on this parameter. While ATP/ADP responses were oscillatory in single 12 
islets, a small and transient dip was present following introduction of high glucose. This has 13 
also been seen in previous studies using identical techniques (19) and may reflect net ATP 14 
consumption secondary to Ca
2+
 transporter activity (48), glucokinase activity (49) and the 15 
initial steps of exocytosis (50), or an uncoupling effect of highly elevated Ca
2+
 levels on 16 
mitochondrial function (21). While similar results were seen using luciferase-based ATP 17 
measures, a change in intracellular pH and Perceval intensity cannot be excluded.  18 
 In summary, we have identified a novel mechanism by which glucocorticoids 19 
maintain beta cell function in rodent and human beta cells through engagement of parallel 20 
cAMP pathways. Failure of this protective feedback loop may contribute to impaired insulin 21 
release during states of glucocorticoid excess (e.g. Cushing’s syndrome).  22 
23 
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FIG.S AND LEGENDS 1 
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Figure 1 - Glucocorticoids suppress cytosolic Ca
2+
 fluxes in response to glucose and glucose 1 
+ KCl. A: Mean ± S.E.M intensity-over-time traces showing glucose- and glucose + KCl-2 
stimulated Ca
2+
 rises in mouse islets treated for 48 hrs with 11-DHC or corticosterone (n = 3 
14-28 islets from 6 animals). B: Representative max intensity projection images showing 4 
impaired Ca
2+
 signaling in control (Con)-, 11-DHC 200 nM-, and corticosterone (Cort)-5 
treated islets (scale bar, 20 µm) (images cropped to show a single islet). C: Summary bar 6 
graph showing a significant reduction in the amplitude of glucose- stimulated Ca
2+
 rises 7 
following treatment with either glucocorticoid (n = 14-28 islets from 6 animals). D: As for C, 8 
but area-under-the-curve (AUC). E: As for C but glucose + KCl. F: Corticosterone and 11-9 
DHC significantly decrease Ca
2+
 spiking frequency at high glucose (representative traces 10 
shown) (n = 14 islets from 3 animals). G: As for F, but summary bar graph showing Ca
2+
 11 
oscillations per minute. H. Cortisone and cortisol blunt glucose- and glucose + KCl-12 
stimulated Ca
2+
 rises in human islets (representative traces shown) (n = 15-18 islets from 3 13 
donors, 48 hrs). I and J: As for H, but summary bar graphs showing amplitude of Ca
2+
 14 
responses to glucose (I) and glucose + KCl (J). K: 11-DHC and corticosterone do not affect 15 
Ca
2+
 responses to the incretin-mimetic, exendin 4 (Ex4) 10 nM (representative traces shown) 16 
(n = 14-17 islets from 3 animals). L and M: As for K, but summary bar graphs showing 17 
oscillation frequency (L) and AUC (M). G3 = 3 mM glucose; G11 = 11 mM glucose; G17 = 18 
17 mM glucose. KCl was applied at 10 mM. *P<0.05, **P<0.01 and NS, non-significant; 19 
one-way ANOVA (Bonferroni’s post hoc test). Corticosterone was applied at 20 nM for 48 20 
hr. Traces in F, H and K share the same F/Fmin scale but are offset in the y-axis. Unless 21 
otherwise stated, data represent the mean ± S.D. 22 
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 1 
Figure 2 – Glucocorticoids impair VDCC function despite preserved beta cell identity and 2 
metabolism. A-F: Expression of mRNA for the beta cell maturity markers Pdx-1 (A-C) and 3 
Nkx6.1 (D-F) are similar in control and 11-DHC/corticosterone-treated islets (n = 4-7 4 
animals, 48 hrs). G: Mean ± S.E.M traces showing no effect of glucocorticoids on maximal 5 
ATP/ADP responses to glucose, measured using the biosensor Perceval. H: As for G, but 6 
summary bar graph showing the amplitude of ATP/ADP rises (n = 7 islets from 4 animals). I: 7 
11-DHC and corticosterone reduce VDCC conductance, as shown by the voltage-current (I-8 
V) relationship (n = 4 animals) (* 11-DHC versus control; #
 
corticosterone versus control). J: 9 
As for I, but representative Ca
2+
 current traces. K-P: Expression levels of the voltage-10 
dependent Ca
2+
 channel α/β subunits Cacna1c (K and L), Cacnb2 (M and N) and Cacna1d (O 11 
and P) are not significantly altered by 11-DHC or corticosterone (n = 4-6 animals, 48 hrs). 12 
G3 = 3 mM glucose; G17 = 17 mM glucose. 
#
/*P<0.05, 
##
/**P<0.01 and NS, non-significant; 13 
30 
 
Student’s t-test, Student’s paired t-test or one-way ANOVA (Bonferroni’s post hoc test). 1 
Corticosterone was applied at 20 nM for 48 hr. Unless otherwise stated, data represent the 2 
mean ± S.D. 3 
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 1 
Figure 3 - Insulin secretion from islets is maintained in the face of excess glucocorticoid. A: 2 
Basal, glucose-stimulated and glucose + KCl-stimulated insulin secretion is unaffected 3 
32 
 
following 48 hr treatment of mouse islets with either 11-DHC or corticosterone (n = 5 1 
animals). B-D: QRT-PCR analyses of Ins1 mRNA expression shows no significant changes 2 
in response to 11-DHC 20 nM (B), 11-DHC 200 nM (C) or corticosterone (D) exposure (n = 3 
4-7 animals). E: Total insulin content is unaffected by exposure to 11-DHC or corticosterone 4 
(n = 3 animals). F: Basal, glucose-stimulated and glucose + KCl-stimulated insulin secretion 5 
is unaffected following 48 hr treatment of human islets with either cortisone 200 nM or 6 
cortisol 20 nM (n = 3 donors). G: As for F, but stimulation index to better account for 7 
differences in basal secretion between islet batches from the different isolation centres. 8 
*P<0.05, **P<0.01 and NS, non-significant; Student’s t-test, one-way ANOVA (Bonferroni’s 9 
post hoc test) or two-way ANOVA. G3 = 3 mM glucose; G17 = 17 mM glucose. 10 
Corticosterone was applied at 20 nM for 48 hr. KCl was applied at 10 mM. Unless otherwise 11 
stated, data represent the mean ± S.D or range. 12 
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 1 
Figure 4 - Glucocorticoids potentiate cAMP signaling. A: Both 11-DHC and corticosterone 2 
(Cort) amplify glucose-stimulated cAMP generation, as measured online using the biosensor 3 
Epac2-camps (FSK, forskolin; positive control) (mean ± S.E.M traces shown) (n = 20-24 4 
islets from 5 animals). B: Summary bar graph showing significant effects of either 5 
glucocorticoid on the AUC of cAMP responses to glucose. C: Representative images of 6 
FRET responses in control-, 11-DHC- and corticosterone (Cort)-treated beta cells expressing 7 
Epac2-camps (scale bar, 10 µm). D: Inhibition of PKA decreases glucose-stimulated insulin 8 
in the presence of 11-DHC but not control (n = 3 animals) (mean and range shown). E: 11-9 
DHC and corticosterone (Cort) increase the fraction of the cell membrane occupied by insulin 10 
34 
 
granules (V/v). F: Representative Structured Illumination Microscopy (SIM) images showing 1 
insulin granules in control-, 11-DHC- and corticosterone (Cort)-treated islets (n = 8 cells 2 
from 3 animals) (scale bar = 5 µm) (lower panel shows zoom-in). G: Cortisone and cortisol 3 
augment glucose-stimulated cAMP generation in human islets (mean ± S.E.M traces shown). 4 
H: Summary bar graph showing significant effects of cortisone and cortisol on the AUC of 5 
cAMP responses to glucose (n = 10-11 islets from 3 donors). I: Glucocorticoid does not 6 
affect cAMP responses to exendin-4 (Ex4) 10 nM (n = 24-46 islets from 4 animals). J: As for 7 
I, but summary bar graph showing AUC of cAMP responses. K and L: Relative (fold-change) 8 
expression levels of Adcy1, 5, 6, 8 and 9 in 11-DHC (K) and corticosterone (L)-treated islets 9 
(n = 4-5 animals). M: Palmitate but not BSA control prevents 11-DHC from augmenting 10 
cAMP responses to glucose (Palm, palmitate) (n = 23-27 islets from 4 animals) (traces 11 
represent mean ± S.E.M). N. As for M, but summary bar graph showing AUC of cAMP 12 
responses. G3 = 3 mM glucose; G11 = 11 mM glucose; G17 = 17 mM glucose. *P<0.05, 13 
**P<0.01 and NS, non-significant; Student’s t-test or one-way ANOVA (with Bonferroni’s 14 
or Tukey’s post hoc test). 11-DHC and corticosterone were applied for 48 hr at 200 nM and 15 
20 nM, respectively. Unless otherwise stated, data represent the mean ± S.D. 16 
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 1 
Figure 5 - Deletion of Hsd11b1 reverses the effects of glucocorticoid on Ca
2+
 signaling. A: 2 
Mean intensity-over-time traces showing a reduction in glucose- and glucose + KCl-3 
stimulated Ca
2+
 rises in Hsd11b1
+/-
 islets treated for 48 hrs with 11-DHC or corticosterone 4 
(Cort) (n = 15-19  islets from 3 animals). B and C: As for A, but summary bar graphs showing 5 
the amplitude of Ca
2+
  responses to glucose (B) and glucose + KCl (C). D: Representative 6 
max intensity projection images showings impaired glucose-stimulated Ca
2+
 rises in control 7 
(Con)-, 11-DHC- and corticosterone-treated Hsd11b1
+/-
 islets (scale bar, 20 µm) (images 8 
cropped to show a single islet). E: Mean ± S.E.M intensity-over-time traces showing intact 9 
glucose- and glucose + KCl-stimulated Ca
2+
 rises in Hsd11b1
-/-
 islets treated for 48 hrs with 10 
11-DHC or corticosterone (n = 19-28  islets from 3 animals). F and G: As for E, but summary 11 
bar graphs showing the amplitude of Ca
2+
 responses to glucose (F) and glucose + KCl (G). H: 12 
Representative max intensity projection images showing similar glucose-stimulated Ca
2+
 13 
rises in control (Con)-, 11-DHC- and corticosterone-treated Hsd11b1
-/-
 islets (scale bar, 20 14 
36 
 
µm) (images cropped to show a single islet). G3 = 3 mM glucose; G17 = 17 mM glucose. 1 
*P<0.05, **P<0.01 and NS, non-significant, one-way ANOVA (Bonferroni’s post hoc test). 2 
11-DHC and corticosterone were applied for 48 hr at 200 nM and 20 nM, respectively. KCl 3 
was applied at 10 mM. Unless otherwise stated, data represent the mean ± S.D. 4 
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 1 
Figure 6 - Deletion of Hsd11b1 reverses the effects of 11-DHC on cAMP signaling. A: Mean 2 
± S.E.M intensity-over-time traces showing cAMP responses to glucose in 11-DHC- and 3 
corticosterone (Cort)-treated Hsd11b1
+/-
 islets (FSK, forskolin; positive control) (n = 15-19 4 
islets from 3 animals). B and C: As for A, but summary bar graphs showing the amplitude (B) 5 
and AUC (C) of cAMP responses. D: Representative images of cAMP responses to glucose 6 
in control (Con)-, 11-DHC- or corticosterone-treated Hsd11b1
+/-
 islets expressing Epac2-7 
camps (scale bar, 10 µm). E: Mean ± S.E.M intensity-over-time traces showing that cAMP 8 
responses to glucose are potentiated by 11-DHC, but not corticosterone, in Hsd11b1
-/-
 islets 9 
(n = 22-23 islets from 3 animals). F and G: As for E, but summary bar graphs showing the 10 
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amplitude (F) and AUC (G) of cAMP responses. H: Representative images of cAMP 1 
responses to glucose in control (Con)-, 11-DHC- and corticosterone-treated Hsd11b1
-/-
 islets 2 
expressing Epac2-camps (scale bar, 10 µm). I: Insulin secretion in response to glucose is 3 
significantly improved in corticosterone- compared to control and 11-DHC-treated Hsd11b1
-/-
 4 
islets (n = 4 animals). J and K: Relative (fold-change) expression levels of Adcy1, 5, 6, 8 and 5 
9 in 11-DHC (J) and corticosterone (K)-treated Hsd11b1
-/-
 islets (n = 5 animals). G3 = 3 mM 6 
glucose; G17 = 17 mM glucose. *P<0.05, **P<0.01 and NS, non-significant, Student’s t-test 7 
or one-way ANOVA (Bonferroni’s post hoc test). 11-DHC and corticosterone were applied 8 
for 48 hr at 200 nM and 20 nM, respectively. KCl was applied at 10 mM. Unless otherwise 9 
stated, data represent the mean ± S.D. 10 
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Figure 7 - 11-DHC effects are mediated through the glucocorticoid receptor. A: The 2 
glucocorticoid receptor antagonist RU486 prevents the suppressive effects of 11-DHC on 3 
glucose- and glucose + KCl-stimulated Ca
2+
 signals (mean ± S.E.M traces shown) (n = 12-13 4 
islets from 4 animals). B and C: As for, A but summary bar graphs showing that 11-DHC 5 
does not affect Ca
2+
 responses to glucose (B) or glucose + KCl (C) in RU486-treated islets. 6 
D: Representative max intensity projection images showing impaired Ca
2+
 rises in 11-DHC-7 
treated islets, which can be reversed using the glucocorticoid receptor antagonist RU486 8 
(scale bar, 20 µm) (images cropped to show a single islet). E: RU486 blocks the effects of 9 
40 
 
corticosterone (Cort) on Ca
2+ 
responses to glucose (n = 14-17 islets from 6 animals). F: As 1 
for E, but RU486 is unable to significantly affect Ca
2+ 
responses to glucose + KCl in 2 
corticosterone-treated islets (n = 14-17 islets from 6 animals). *P<0.05, **P<0.01 and NS, 3 
non-significant, one-way ANOVA (Bonferroni’s post hoc test). 11-DHC and corticosterone 4 
were applied for 48 hr at 200 and 20 nM, respectively. KCl was applied at 10 mM. Unless 5 
otherwise stated, data represent the mean ± S.D. 6 
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 1 
 Figure 8 - Glucocorticoids impair KATP-independent signals to reduce ionic fluxes in 2 
glucose-stimulated beta cells. This is further exacerbated by Hsd11b1, which increases 3 
availability of more active glucocorticoid (11-DHC/cortisone -> corticosterone/cortisol) in a 4 
paracrine manner. However, insulin secretion is preserved, since glucocorticoids are able to 5 
reprogram the beta cell signaling cassette towards a cAMP phenotype, most likely through 6 
upregulation of specific Adcy isoforms. 7 
